Key result
Vaccination with prion peptide-displaying virus-like particles significantly increased mean survival time to 240 days compared with 202 days in control mice challenged with scrapie.
Why the study?
No approved therapy exists for fatal prion diseases, and immunisation is hindered by mammalian self-tolerance to normal cellular prion protein.
Does vaccination with prion peptide-displaying VLPs prolong survival in scrapie-infected mice?
Population
C57/BL6 mice subsequently challenged intraperitoneally with murine RML prion strain
Comparison
Nine prion peptide variants presented by hamster polyomavirus capsid protein VP1/VP2-derived VLPs vs control
Authors
Loading...
Extends preclinical VLP vaccine data in scrapie models; leaves open translation to human prion disease prevention.
Does vaccination with prion peptide-displaying VLPs prolong survival in scrapie-infected mice?
Absolute Event Rate: 240% vs 202%
Vaccination with virus-like particles presenting PrP peptides significantly prolongs survival in scrapie-infected mice, offering a potential prophylactic strategy against prion diseases.
Eiden et al. (2021) studied Scrapie (prion disease). Vaccination with prion peptide variants presented by hamster polyomavirus capsid protein VP1/VP2-derived VLPs vs. Control group was evaluated on Mean survival time. Vaccination with prion peptide-displaying virus-like particles significantly increased mean survival time to 240 days compared with 202 days in control mice challenged with scrapie.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: